MSB 7.69% $1.19 mesoblast limited

Ann: Mesoblast Update on COVID-19 ARDS Trial, page-347

  1. 2,261 Posts.
    lightbulb Created with Sketch. 367
    People stop over reacting. ARDs was a bonus product not even part of their plan. Also secondary endpoints likely to be very favourable.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.